Turning Point Therapeutics Profit Margin

Turning Point Therapeutics posts a profit margin of -33130.6% as of June 2022. That compares with -283.3% in the prior-year period — down 11594.7% year over year. That is below the Healthcare sector average of 15.29%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Turning Point Therapeutics's profit margin was -283.3%. The latest reading is -33130.6% — a 11594.7% year-over-year decrease (period ending June 2022). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 15.29% is typical. Turning Point Therapeutics's -33130.6% is lower that level. That is roughly 216740.6% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Turning Point Therapeutics's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -33130.6% as of June 2022; use YoY and peer views to separate noise from signal.

Context for TPTX's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 15.29%), and (3) consistency with growth and profitability. This page covers the first two; Turning Point Therapeutics's other metric pages and overview cover the third.